Tumor growth is influenced by interactions between malignant cells and the tumor stroma. Although the normal host microenvironment is nonpermissive for neoplastic progression, tumor-reactive stroma, characterized by the presence of activated fibroblasts, promotes neoplastic growth and metastasis. Secreted protein, acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that is capable of inhibiting the growth of several different types of cancer. Recently, we reported that SPARC also impairs the growth of xenografts comprised of 293 cells. In this study, we show that in addition to enhancing stroma formation, SPARC prevents fibroblast activation in 293 xenografts, suggesting that the anticancer effects of SPARC may be due, at least in part, to the formation of tumor stroma that is not supportive of tumor growth. In vitro, 3T3 fibroblasts cocultured with SPARC-transfected 293 cells remain negative for a-smooth muscle actin, whereas wild-type 293 cells induce fibroblast activation. Moreover, activation of 3T3 cells and primary fibroblasts by transforming growth factor b is blocked by SPARC treatment. We also demonstrate that SPARC significantly increases basic fibroblast growth factor-induced fibroblast migration in vitro, indicating that it may recruit host fibroblasts to the tumor stroma. Taken together, our results suggest that in addition to blocking angiogenesis, SPARC may inhibit tumor growth by promoting the assembly of stroma that is nonpermissive for tumor progression.
Introduction
It is well recognized that the tumor microenvironment plays a critical role in regulating tumor growth, and that the interactive signaling between neoplastic and stromal cells strongly influences tumor phenotype. Normal tissue stroma provides biochemical cues that constrain epithelial cells and maintain normal tissue homeostasis (Mueller and Fusenig, 2004) . Cancer cells can induce changes in the adjacent stroma leading to conditions that will actively support tumor progression (Olumi et al., 1999) . This 'reactive' tumor stroma has been described as 'desmoplasia' and is characterized by the presence of activated fibroblasts, extracellular matrix (ECM) components, inflammatory and immune cells, as well as newly formed blood and lymph vessels. Activated fibroblasts, or myofibroblasts, which express a-smooth muscle actin (SMA), are also known to be present in specialized normal tissues, areas of inflammation, tissues undergoing wound healing, and in various types of 'desmoplastic' tumor stroma-generated granulation tissue (Beacham and Cukierman, 2005) .
A poorer prognosis has been associated with carcinomas with desmoplastic stroma (Maeshima et al., 2002; Yazhou et al., 2004) , and laboratory studies support the concept that myofibroblasts are capable of enhancing tumor progression. Activated fibroblasts explanted from human prostate carcinomas can promote epithelialmesenchymal transition of SV40-transformed prostate epithelial cell lines (Olumi et al., 1999) . A similar tumorpromoting effect of stromal fibroblasts has been reported in human squamous cell carcinomas of the skin and in breast cancer. In contrast, fibroblasts derived from normal breast tissue inhibit the growth of breast cancer cells (Mueller and Fusenig, 2004) . Taken together, these studies indicate that myofibroblasts in tumor-reactive stroma are biologically distinct from normal fibroblasts, and that oncogenic signals from the activated fibroblasts play a central role in promoting tumorigenesis.
SPARC, also known as osteonectin and BM-40, is a matricellular glycoprotein that mediates cell-matrix interactions. In addition to its counteradhesive and antiproliferative functions, SPARC modulates angiogenesis and regulates the production, assembly and organization of the extracellular matrix (Sage et al., 1984; Bradshaw and Sage, 2001) . The role of SPARC in tumorigenesis is complex and appears to be cell-type specific owing to its diverse functions in a given microenvironment. Although the expression of SPARC has been identified as a marker of malignant behavior in some cancers, we and others have shown that SPARC functions as a tumor suppressor in neuroblastoma (NB), breast, pancreatic, lung and ovarian cancer (Framson and Sage, 2004) . Recently, we have demonstrated that SPARC also impairs the growth of 293-cell xenografts (Chlenski et al., 2006) . Interestingly, the tumor stromal component and the quantity of mature collagen bundles were dramatically increased in the 293-cell xenografts with forced SPARC expression compared with control tumors. We hypothesized that the SPARC-induced changes in the tumor microenvironment were responsible, at least in part, for its anticancer effects.
In this study, we examined the effects of SPARC on fibroblast activation and report that SPARC is capable of inhibiting the differentiation of myofibroblasts in vivo and in vitro. We also demonstrate that SPARC strongly enhances basic fibroblast growth factor (bFGF)-induced fibroblast migration, whereas its effect on bFGFinduced fibroblast proliferation is minimal. Our studies indicate that in addition to blocking angiogenesis, SPARC is capable of modifying the tumor stroma by recruiting host fibroblasts and blocking fibroblast activation.
Results

SPARC inhibits fibroblast activation in vivo
We recently established a nude mouse xenograft model of 293 cells with forced SPARC expression. Compared with wild-type and vector-transfected control tumors, the growth of the SPARC-transfected xenografts was impaired and angiogenesis was inhibited (Chlenski et al., 2006) . Histologic examination of the tumors demonstrates an increase in the quantity of stroma in the SPARC-transfected tumors compared with controls ( Figure 1a and b) . The presence of fibroblasts in the stromal components of the tumors was confirmed with fibroblast-specific S100a4 staining (Strutz et al., 1995) and stromal expression of collagen was evaluated with Masson trichrome staining and collagen I immunostaining (Figure 1 ). Immunofluorescence studies were performed to evaluate SPARC expression in the tumors, and as shown in Figures 1a and b , the SPARCtransfected 293 cells expressed high levels of this matricellular protein. Low to undetectable levels of SPARC were seen in the mouse fibroblasts in the stromal component of the tumor, and SPARC was not detected in the wild-type and vector-transfected 293 tumor cells. To specifically examine the effect of tumorproduced SPARC on fibroblast activation, we stained the SPARC-transfected and control 293 xenografts for smooth muscle actin (SMA), a marker of fibroblast activation. The 293 cells were visualized with a cytokeratin 18 antibody. As shown in the Figure 2 , a high proportion of SMA-positive cells was seen in the stromal components of the wild-type and vector-control 293 xenografts. In contrast, only small numbers of SMA-positive fibroblasts were detected in the 293 xenografts with forced SPARC expression, even though these tumors contained abundant quantities of stromal tissue.
SPARC inhibits fibroblast activation in vitro
To further investigate the effects of SPARC on fibroblast activation, we cocultured NIH 3T3 fibroblasts and SPARC-transfected or control 293 cells. Similar to the 293 xenograft model, control 293 cells induced fibroblast activation manifested by the elevated expression of SMA (Figure 3 ). In addition, collagen I expression, which is often associated with fibroblast activation, was also elevated. In contrast, 3T3 fibroblasts cultured with 293 cells expressing SPARC remained largely negative for SMA. Similarly, fibroblasts treated with conditioned media collected from the vector-control and parental 293 cells expressed SMA. In contrast, only low levels of SMA were detected in 3T3 cells cultured with conditioned media collected from the SPARC-transfected 293 cells (Figures 3 and 4a) .
293 cells are known to express bFGF (Hamid et al., 2005) and transforming growth factor b (TGFb) (Arrick et al., 1992) , and both of these cytokines influence stromal formation and fibroblast activation (Kalluri and Zeisberg, 2006) . To determine if the inhibition of fibroblast activation seen with SPARC treatment was due to SPARC-induced changes in the levels of bFGF or TGFb expression, semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed with RNA isolated from control and SPARC-transfected 293 cells. No significant change in the level of expression of either cytokine was associated with SPARC expression (data not shown). Furthermore, immunofluorescence studies demonstrated that the expression levels of bFGF and TGFb in the stromal tissue of the SPARC-transfected 293 xenografts and control tumors were similar (data not shown).
To investigate if SPARC was capable of inhibiting cytokine-induced fibroblast activation, we treated NIH 3T3 cells with bFGF and TGFb in the presence and absence of SPARC. bFGF did not induce fibroblast activation at any of the concentrations tested, ranging from 0.1 pg/ml to 100 ng/ml, for 24, 48 and 72 h. We also found that treatment with SPARC alone or in combination with 10 ng/ml bFGF for 48 h had no significant effect on fibroblast activation, although a slight elevation of SMA expression was observed in all experiments with and without cytokines, when the concentration of SPARC was above 1 mg/ml (Figure 4b) . However, the level of SMA expression in 3T3 cells increased 2.9270.30 times following 48 h of treatment with 10 ng/ ml TGFb. As shown in Figure 4b , treatment with serial 10 Â dilutions of rhSPARC from 1 ng/ml to 100 mg/ml caused a concentration-dependent downregulation of SMA expression in the fibroblasts activated with 10 ng/ ml TGFb for 48 h. TGFb treatment also induced low SPARC has limited effect on fibroblast proliferation, but potently stimulates fibroblast migration in vitro To investigate the mechanism by which SPARC may induce fibroblast accumulation in the 293 xenografts, we tested the effects of SPARC on proliferation and migration of 3T3 cells, using serum-free and serumcontaining media collected from the parental, vectortransfected and SPARC-transfected 293 cells. Although the presence of SPARC in the media did not impact fibroblast proliferation, the migration of bFGF-stimulated fibroblasts was significantly enhanced by the media collected from SPARC-transfected 293 cells (Figure 6a  and b) .
Initial studies performed with serial 10 Â dilutions of bFGF or TGFb from 0.01 pg/ml to 100 ng/ml indicated that 10 ng/ml was the optimal concentration for both bFGF and TGFb to stimulate proliferation of 3T3 fibroblasts. Treatment with bFGF for 48 h increased fibroblast proliferation 1.9270.23 times, while it was increased 1.5970.33 times following treatment with TGFb. When fibroblasts were stimulated with 10 ng/ml of bFGF or TGFb, the addition of SPARC at a range of concentrations from 1 pg/ml to 100 mg/ml did not significantly alter the rate of proliferation. Without cytokine stimulation, fibroblast proliferation was weakly enhanced by SPARC at the concentrations above 1 mg/ml (Figure 6c ).
Migration assays with serial 5 Â dilutions from 0.05 pg/ml to 100 ng/ml demonstrated that the optimal concentration of bFGF-induced fibroblast migration SPARC influences tumor stroma A Chlenski et al was 4 ng/ml. At this concentration, the migration of 3T3 fibroblasts was enhanced 1.970.6 times compared with untreated cells. However, with the addition of 4 mg/ml SPARC, the relative stimulation of fibroblast migration increased from 100% when treated with bFGF alone, to a maximum of 4127104% (Po0.05). The calculated EC 50 of the stimulation of bFGF-induced fibroblast migration was B1 mg/ml of SPARC (Figure 6d ). TGFb did not significantly stimulate the migration of 3T3 fibroblasts at any concentration between 0.05 pg/ml and 100 ng/ml, and the addition of SPARC had no significant effect on the migration of untreated cells or cells treated with 5 ng/ml TGFb.
Discussion
SPARC is an extracellular matrix protein that plays a critical role in mediating cell-matrix interactions. Although SPARC potently inhibits angiogenesis in vivo, its role in tumor growth remains controversial and appears to be cell-type specific. We and others have demonstrated that SPARC is an endogenous negative regulator of several types of cancer, and exogenous treatment with SPARC potently inhibits NB tumor growth (Chlenski et al., 2002) . Forced expression of SPARC in 293 cells also results in reduced growth of mouse xenografts and is associated with a reduced number of tumor blood vessels and a dramatic increase in the quantity of tumor stroma and deposition of ECM (Chlenski et al., 2006) . As tumor-reactive desmoplastic stroma is known to promote angiogenesis and play a central role in supporting tumor growth, we hypothesized that SPARC may prevent the activation of tumor stroma by blocking myofibroblast differentiation and forming a non-permissive microenvironment for neoplastic progression.
In support of this hypothesis, we identified only rare myofibroblasts in the 293 xenografts with SPARC expression, whereas a large proportion of SMA-positive fibroblasts were apparent in control tumors. Although the SPARC-transfected 293 tumors lacked activated fibroblasts, these tumors contained large amounts of mature collagen owing to the high numbers of fibroblasts in the stroma. In contrast, the presence SPARC influences tumor stroma A Chlenski et al promoting tumor growth (Powell et al., 1999) . The functional contributions of myofibroblasts to tumor growth remain poorly understood, although recent studies indicate that these cells secrete stromal cellderived factor 1 (SDF-1), a protein that is capable of recruiting endothelial precursor cells into carcinomas and promoting angiogenesis (Orimo et al., 2005) . A variety of factors contribute to the induction of myofibroblast differentiation, including stem cell factor (SCF), platelet-derived growth factor (PDGF) and granulocytemacrophage colony-stimulating factor (GM-CSF) (Powell et al., 1999) . It remains unclear if SPARC inhibits myofibroblast differentiation by interacting with one or more of these factors. However, SPARC is capable of suppressing the activity of PDGF and vascular endothelial growth factor (VEGF) by directly binding to these ligands (reviewed in Yan and Sage, 1999) . TGFb is required to induce the expression of fibroblast activation markers a-SMA and collagen I, cause myofibroblast differentiation, and for the formation of granulation tissue in vivo (Desmouliere et al., 1993) . Exogenous SPARC can directly bind TGFb/ TGFb receptor type II complex and enhance the effect of TGFb through SMAD and JNK pathways (Schiemann et al., 2003; Francki et al., 2004) . Here, we show that SPARC blocks fibroblast activation induced by TGFb and inhibits expression of fibroblast activation markers. Similar inhibition of SMA, collagen I and fibronectin by SPARC was recently observed in lens epithelial cells (Perdue and Yan, 2006) . The demonstration that exogenously added SPARC can be internalized by cells in this and previous studies (Barker et al., 2005) suggests that SPARC inhibition of TGFb signaling may function via a SMAD-independent mechanism (Wilkes et al., 2005) , perhaps by modifying stress fiber assembly during fibroblast activation by small GTPase Rho (Hall, 1998) .
Enhanced tumor growth has been reported in SPARC null mice, consistent with its function as a tumor suppressor. Interestingly, the tumors that develop in SPARC null mice exhibit significant alterations in the production and organization of the extracellular matrix components, and these changes are believed to create a permissive environment for the accelerated tumor growth and invasion of cancer cells (Brekken et al., 2003) . Our study supports the concept that SPARC influences tumor growth by regulating tumor stroma assembly. SPARC generally inhibits cell proliferation, although exogenous treatment with SPARC has been shown to have a bimodal effect on the proliferation of different types of cells. It delays cell cycle in the G 1 phase of endothelial cells (Funk and Sage, 1991) and smooth muscle cells stimulated with PDGF (Motamed et al., 2002) and inhibits proliferation of mesangial cells (Pichler et al., 1996) and TGFb-treated epithelial cells (Schiemann et al., 2003) , but has been shown to stimulate fibroblast proliferation (Funk and Sage, 1993) . In our experiments, SPARC only weakly stimulated 3T3 fibroblast proliferation at relatively high concentrations. However, SPARC dramatically increased the migration of bFGF-induced fibroblasts, indicating that SPARC most likely induces stromal tissue formation by recruiting residential fibroblasts rather than by increasing fibroblast proliferation.
Although Paget (1889) proposed more than 100 years ago that environment (soil) could influence the growth of tumors (seeds), evidence that tumor-host cross-talk affects the behavior of tumor cells has been obtained only recently. We and others have shown that tumor phenotype can be modified by the cellular composition of its microenvironment (Skobe et al., 1997; Liu et al., 2005) . Stromal therapy has now emerged as a strategy for cancer treatment, and clinical studies have shown that anti-angiogenic agents are effective treatment for many types of cancer (Meyerhardt and Mayer, 2005) . Recent studies indicate that VEGFR2 blockade not only results in inhibited angiogenesis, but also impedes tumor invasion by modifying other components of the tumor stroma (Skobe et al., 1997) . SPARC is another example of a molecule that is capable of inhibiting angiogenesis and altering the composition of the tumor stroma. By inhibiting vascular cells, recruiting fibroblasts and preventing fibroblast activation, SPARC may play a role in 'normalizing' the tumor stroma and creating a microenvironment that is non-permissive for tumor growth. Further studies investigating SPARC as a novel endogenous therapeutic candidate for NB and other types of cancers are warranted.
Materials and methods
Cell culture and rhSPARC production NIH 3T3 mouse fibroblasts and human embryonic kidney 293 cells (ATCC, Manassas, VA, USA) were cultured in 5% CO 2 in Dulbecco's modified Eagle's medium medium (DMEM) (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (GIBCO). For collection of the SPARC influences tumor stroma A Chlenski et al conditioned media (CM), cells were washed 3 times with phosphate-buffered saline (PBS) and incubated with serumfree DMEM for 4 h. The media was then replaced, conditioned for 72 h, and collected following centrifugation. For the coculture studies, equal numbers of 3T3 fibroblasts or a mixture of 293 and 3T3 cells were plated on gelatinized coverslips in a 24-well plate, grown to confluency and then processed for immunostaining. Recombinant human SPARC (rhSPARC) was purified from 293 cells transfected with human SPARC cDNA as described (Chlenski et al., 2006) . Primary human fibroblasts MKL were isolated and cultured as described (Rosen et al., 1987) .
Mouse xenografts
Wild-type 293 cells, control 293 cells transfected with empty vector and SPARC-transfected 293 clones were inoculated subcutaneously into nude mice, and paraffin sections of the resulting xenografts were prepared as described previously (Chlenski et al., 2006) . Animals were treated according to the NIH guidelines for animal care and use and protocols approved by the Animal Care and Use Committee at Northwestern University.
Immunofluorescence Cultured cells grown on coverslips were fixed with 1% paraformaldehyde at room temperature for 30 min, washed twice with PBS and permeabilized with 70% ethanol at À201C for at least 20 min. Xenograft sections were pre-processed for immunofluorescence studies as described (Chlenski et al., 2006 
Fibroblast activation assays
To analyse the effects of cytokine and SPARC treatments on fibroblast activation in vitro, 5 Â 10 4 3T3 fibroblasts were plated on gelatinized coverslips in 24-well plates, grown in DMEM with 10% FBS overnight and treated with the indicated concentrations of TGFb1 (R&D) or bFGF (R&D), with or without rhSPARC. Coverslips were then fixed and immunostained for SMA. For image quantitative analysis, at least three areas of each sample were photographed at 100 Â magnification, fluorescence quantified with ImagePro software (Media Cybernetics, Silver Spring, MD, USA), and the data were evaluated using the Student's t-test.
For the Western blot analysis of fibroblast activation, 70-90% confluent cells grown on gelatinized dishes were treated with 5 mg/ml of rhSPARC and 10 ng/ml TGFb separately or in combination for 48 h. Untreated cells were used as control. After treatment, lysates were prepared and analyzed by Western blotting as described (Chlenski et al., 2006) . Anti-SMA antibody was used at 1:500 dilution. Equal loading was verified by staining with anti b-actin antibody (Sigma, St Louis, MO, USA) at 1:1000 dilution.
Fibroblast proliferation and migration assays Proliferation rates were determined for 3T3 fibroblasts grown in 96-well plates treated with the CM or indicated concentrations of bFGF or TGFb (R&D) in DMEM containing 0.01% bovine serum albumin (BSA) for different times with the CellTiter cell proliferation assay (Promega, Madison, WI, USA).
The migration of 3T3 fibroblasts was examined in a modified Boyden chamber in CM or DMEM media containing 0.01% BSA and the test substances, following the protocol previously described for endothelial cell migration (Chlenski et al., 2002) . In some assays, serial dilutions of rhSPARC were added. The data were collected at least in triplicate from three independent experiments and evaluated using the Student's t-test.
